Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial

(101/122; 95% CI: 74.9%‐89.0%). Per-protocol cure rates were: CAO, 78.0% (96/123; 95% CI: 69.7%‐85.0%) and LAO, 83.1% (98/118; 95% CI: 75.0%‐89.3%). There were no statistically significant differences in effectiveness between the two regimens. In addition, no relevant differences in compliance or adverse effects were demonstrated. Conclusions: Levofloxacin-based treatment for H. pylori infection did not improve upon the eradication rate of the standard clarithromycin-based triple therapy in this study. This may reflect the progressive increase in in vitro resistance rates to levofloxacin observed in our region.